Generic Clearance for the Collection of Qualitative Feedback on Food and Drug Administration Service Delivery

ICR 202011-0910-002

OMB: 0910-0697

Federal Form Document

Forms and Documents
Document
Name
Status
Supplementary Document
2020-11-27
Supporting Statement B
2020-11-27
Supporting Statement A
2020-11-27
ICR Details
0910-0697 202011-0910-002
Active 201710-0910-006
HHS/FDA Generic
Generic Clearance for the Collection of Qualitative Feedback on Food and Drug Administration Service Delivery
Extension without change of a currently approved collection   No
Regular
Approved without change 12/30/2020
Retrieve Notice of Action (NOA) 11/27/2020
Previous terms continue: OMB approves this collection for a period of three years. To request approval of information collections under this generic approval, the agency must do the following: 1) Unless an agency is using multiple modes of collection (e.g., paper forms and electronic submissions), provide a Generic Clearance Submission Template for each Instrument; 2) If the agency is using multiple modes of collection (e.g., paper forms and electronic submissions), the same Generic Clearance Submission Template may be used for both instruments; 3) each Generic Clearance Submission Template must be uploaded as a Supplementary document using a naming convention that allows the public to identify the associated instrument; 4) submit no more than five Generic Submission Templates with each request.
  Inventory as of this Action Requested Previously Approved
12/31/2023 36 Months From Approved 12/31/2020
15,752 0 14,925
8,491 0 8,491
0 0 0

The information collected from our customers and stakeholders will help ensure that users have an effective, efficient, and satisfying experience with FDA's programs. This feedback will provide insights into customer or stakeholder perceptions, experiences and expectations, provide an early warning of issues with service, or focus attention on areas where communication, training or changes in operations might improve delivery of products or services. These collections will allow for ongoing, collaborative and actionable communications between FDA and its customers and stakeholders. It will also allow feedback to contribute directly to the improvement of program management.

EO: EO 12862 Name/Subject of EO: Setting Customer Service Standards
  
None

Not associated with rulemaking

  85 FR 18989 04/03/2020
85 FR 70181 11/04/2020
Yes

0

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 15,752 14,925 0 27 800 0
Annual Time Burden (Hours) 8,491 8,491 0 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No

$400,000
Yes Part B of Supporting Statement
    Yes
    No
No
No
No
No
Ila Mizrachi 301 796-7726 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
11/27/2020


© 2024 OMB.report | Privacy Policy